Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Greatly undervalued vs peers
About
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1...
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, undervalued o
Target Price
The average target price of GRF.MC is 15 and suggests 67% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell